---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-005825"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2022-04-20T23:59:59+00:00"
generated_at: "2026-06-26T06:07:19.470839+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sutro Biopharma amends Tasly license for STRO-002; gets $25M initial, up to $350M in milestones

## Summary
- Amendment to Tasly license for STRO-002 in Greater China (China, HK, Macau, Taiwan).
- Initial payment revised to $25M; $15M escrow in Q2 2022 payable on regulatory milestones.
- Additional potential milestone payments up to $350M for development, regulatory, commercialization.
- Tasly retains exclusive rights to develop and commercialize STRO-002 in the region.
- Amendment effective April 18, 2022; full terms to be filed in Q2 2022 10-Q.

## SEC filing metadata
- accession: 0000950170-22-005825
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2022-04-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000095017022005825/0000950170-22-005825-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000095017022005825/stro-20220418.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-005825
- JSON: https://secwatch.observer/filing/0000950170-22-005825.json
- Plain text: https://secwatch.observer/filing/0000950170-22-005825.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.